Enzalutamide

Enzalutamide is an oral medication used to treat metastatic prostate cancer. Metastatic cancer is a type of cancer that has spread from its original location, in this case, the prostate, to other parts of the body. Enzalutamide works by inhibiting the growth and spread of cancer cells in the body.
Enzalutamide is specifically designed for use in men whose cancer has progressed despite treatment with other drugs, such as androgen deprivation therapy and taxane-based chemotherapy. It is a potent and selective inhibitor of the androgen receptor, a protein found in prostate cancer cells that promotes their growth when activated by testosterone or other androgens. By blocking the androgen receptor, enzalutamide deprives prostate cancer cells of the hormonal signals they need to grow and multiply.
In clinical trials, enzalutamide has demonstrated significant benefits in terms of improving survival, delaying cancer progression, and reducing the need for additional therapies. It is generally well-tolerated, with common side effects including fatigue, hot flashes, and diarrhea. However, enzalutamide may cause serious side effects in some patients, such as seizures, falls, and fractures, particularly in those with pre-existing risk factors.
Overall, enzalutamide is a valuable treatment option for men with metastatic prostate cancer who have progressed despite prior therapies. It is essential for patients to discuss the potential benefits and risks of enzalutamide with their healthcare providers to determine if it is the right choice for their individual circumstances.